By pursuing one of the prevalent edited genes, GM2A, we uncover an unprecedented link of regulated catabolism to GSC stemness, and we provide a series of proof-of-concept experiments for exploiting the TYK2/ADAR1/GM2A axis as a potential strategy for GBM treatment. Here, GM2A is linked to glioblastoma.